Research ArticleChemotherapy, Antibiotics, and Gene Therapy
The selective Syk inhibitor P505-15 inhibits B cell signaling and function in vitro and in vivo, and augments the activity of fludarabine in chronic lymphocytic leukemia
Stephen E Spurgeon, Greg Coffey, Luke B Fletcher, Russell Burke, Jeffrey W Tyner, Brian J. Druker, Andreas Betz, Francis DeGuzman, Yvonne Pak, Dale Baker, Anjali Pandey, Stanley Hollenbach, Uma Sinha and Marc M Loriaux
Journal of Pharmacology and Experimental Therapeutics December 7, 2012, jpet.112.200832; DOI: https://doi.org/10.1124/jpet.112.200832
Stephen E Spurgeon
1 Knight Cancer Institute at Oregon Health & Science University;
Greg Coffey
2 Portola Pharmaceuticals;
Luke B Fletcher
3 University of Southern California;
Russell Burke
4 Knight Cancer Institute at Oregon Health & Science Univeristy;
Jeffrey W Tyner
4 Knight Cancer Institute at Oregon Health & Science Univeristy;
Brian J. Druker
4 Knight Cancer Institute at Oregon Health & Science Univeristy;
Andreas Betz
2 Portola Pharmaceuticals;
Francis DeGuzman
2 Portola Pharmaceuticals;
Yvonne Pak
5 Portola;
Dale Baker
2 Portola Pharmaceuticals;
Anjali Pandey
2 Portola Pharmaceuticals;
Stanley Hollenbach
2 Portola Pharmaceuticals;
Uma Sinha
6 Potola Pharmaceuticals
Marc M Loriaux
4 Knight Cancer Institute at Oregon Health & Science Univeristy;
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleChemotherapy, Antibiotics, and Gene Therapy
The selective Syk inhibitor P505-15 inhibits B cell signaling and function in vitro and in vivo, and augments the activity of fludarabine in chronic lymphocytic leukemia
Stephen E Spurgeon, Greg Coffey, Luke B Fletcher, Russell Burke, Jeffrey W Tyner, Brian J. Druker, Andreas Betz, Francis DeGuzman, Yvonne Pak, Dale Baker, Anjali Pandey, Stanley Hollenbach, Uma Sinha and Marc M Loriaux
Journal of Pharmacology and Experimental Therapeutics December 7, 2012, jpet.112.200832; DOI: https://doi.org/10.1124/jpet.112.200832
Research ArticleChemotherapy, Antibiotics, and Gene Therapy
The selective Syk inhibitor P505-15 inhibits B cell signaling and function in vitro and in vivo, and augments the activity of fludarabine in chronic lymphocytic leukemia
Stephen E Spurgeon, Greg Coffey, Luke B Fletcher, Russell Burke, Jeffrey W Tyner, Brian J. Druker, Andreas Betz, Francis DeGuzman, Yvonne Pak, Dale Baker, Anjali Pandey, Stanley Hollenbach, Uma Sinha and Marc M Loriaux
Journal of Pharmacology and Experimental Therapeutics December 7, 2012, jpet.112.200832; DOI: https://doi.org/10.1124/jpet.112.200832
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement